National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 5) (PB 41 of 2016) (Cth)

PB 41 of 2016

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016
(No. 5)

National Health Act 1953

I, PENNY SHAKESPEARE, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 27^th May 2016

PENNY SHAKESPEARE
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health

1 Name of Instrument

(1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 5).
(2) This Instrument may also be cited as PB 41 of 2016.

2 Commencement

This Instrument commences on 1 June 2016.
3 Amendment of National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)
Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).

Schedule 1 Amendments

Schedule 1, entry for Acarbose in each of the forms: Tablet 50 mg; and Tablet 100 mg
(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a

Acarbose Mylan

AF

MP NP

90

5

90

(b)insert in the column headed “Schedule Equivalent” for the brands “Glucobay 50” and “Glucobay 100” respectively: a

Schedule 1, entry for Alendronic Acid
(a)omit:

Chem mart Alendronate 70mg

CH

MP NP

C4882 C4885 C4889

4

5

4

(b)omit:

Terry White Chemists Alendronate 70mg

TW

MP NP

C4882 C4885 C4889

4

5

4

Schedule 1, entry for Ampicillin in the form Powder for injection 500 mg (as sodium)
(a)omit:

Ibimicyn

JU

PDP

5

0

5

(b)omit:

Ibimicyn

JU

MP NP

5

1

5

Schedule 1, entry for Ampicillin in the form Powder for injection 1 g (as sodium)
(a)omit:

Ibimicyn

JU

PDP

5

0

5

(b)omit:

Ibimicyn

JU

MP NP

5

1

5

Schedule 1, entry for Arachidonic acid and docosahexaenoic acid with carbohydrate
omit from the column headed “Circumstances”: C4434 substitute: C6141
Schedule 1, entry for Azacitidine
(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a

Azadine

RZ

MP

See Note 3

See
Note 3

1

D(100)

(b)insert in the column headed “Schedule Equivalent” for the brand “Vidaza”: a

Schedule 1, entry for Benzydamine
substitute:

Benzydamine	Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL	Oral application	Difflam	IA	PDP	C5732	1	0	1
MP NP	C5672 C6197	P5672	1	1	1
MP NP	C5672 C6197	P6197	1	3	1

Schedule 1, entry for Bisacodyl
substitute:

Bisacodyl	Suppositories 10 mg, 10	Rectal	a	Dulcolax	BY	MP NP	C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139	P6139	3	3	1
a	Petrus Bisacodyl Suppositories	PP	MP NP	C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139	P6139	3	3	1
a	Dulcolax	BY	MP NP	C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139	P5640 P5775 P5819 P5823 P5851 P5866 P5879	3	5	1
a	Petrus Bisacodyl Suppositories	PP	MP NP	C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139	P5640 P5775 P5819 P5823 P5851 P5866 P5879	3	5	1
a	Dulcolax	BY	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
a	Petrus Bisacodyl Suppositories	PP	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
Suppositories 10 mg, 12	Rectal	Petrus Bisacodyl Suppositories	PP	MP NP	C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139	P6139	3	3	1
MP NP	C5640 C5775 C5819 C5823 C5851 C5866 C5879 C6139	P5640 P5775 P5819 P5823 P5851 P5866 P5879	3	4	1
MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
Enemas 10 mg in 5 mL, 25	Rectal	Bisalax	AS	MP NP	C5613 C5640 C5685 C5720 C5775 C5776 C5804 C6139	P5613 P5640 P5685 P5720 P5775 P5776 P5804	1	2	1
MP NP	C5613 C5640 C5685 C5720 C5775 C5776 C5804 C6139	P6139	1	3	1
MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
Tablet 5 mg	Oral	Lax-Tab	AE	MP NP	C5613 C5640 C5685 C5720 C5775 C5776 C5804 C6139	P5613 P5640 P5685 P5720 P5775 P5776 P5804	200	2	200
MP NP	C5613 C5640 C5685 C5720 C5775 C5776 C5804 C6139	P6139	200	3	200
MP	See Note 2	See Note 2	See Note 2	See Note 2	200	C(100)

Schedule 1, entry for Capecitabine in each of the forms: Tablet 150 mg; and Tablet 500 mg
omit from the column headed “Responsible Person” for the brand “Capecitabine MYX”: YN substitute: OC
Schedule 1, entry for Carbomer
substitute:

Carbomer	Eye gel 2 mg per g, single dose units 0.6 mL, 30	Application to the eye	Viscotears Gel PF	AQ	AO MP NP	C6172	3	5	1
Eye gel 2 mg per g, 10 g	Application to the eye	a	Optifresh eye gel	PP	AO NP	C6153	1	5	1
MP	C6153 C6185	P6153	1	5	1
a	PAA	IQ	AO NP	C6153	1	5	1
MP	C6153 C6185	P6153	1	5	1
a	Viscotears	AQ	AO NP	C6153	1	5	1
MP	C6153 C6185	P6153	1	5	1
a	Optifresh eye gel	PP	MP	C6153 C6185	P6185	1	11	1
a	PAA	IQ	MP	C6153 C6185	P6185	1	11	1
a	Viscotears	AQ	MP	C6153 C6185	P6185	1	11	1

Schedule 1, entry for Carbomer 974
substitute:

Carbomer 974

Ocular lubricating gel 3 mg per g, single dose units 0.5 g, 30

Application to the eye

Poly Gel

AQ

AO MP NP

C6172

3

5

1

Schedule 1, entry for Carmellose
omit:

Eye drops containing carmellose sodium 2.5 mg per mL, single dose units 0.6 mL, 24	Application to the eye	TheraTears	CX	MP NP	C1359	4	5	1
AO	C2802	4	5	1
Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Cellufresh	AG	MP NP	C1359	3	5	1
AO	C2802	3	5	1
Optifresh Tears	PP	MP NP	C1359	3	5	1
AO	C2802	3	5	1
Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Celluvisc	AG	MP NP	C1359	3	5	1
AO	C2802	3	5	1
Optifresh Plus	PP	MP NP	C1359	3	5	1
AO	C2802	3	5	1
Ocular lubricating gel containing carmellose sodium 10 mg per mL, single dose units 0.6 mL, 28	Application to the eye	TheraTears	CX	MP NP	C1359	3	5	1
AO	C2802	3	5	1

substitute:

Eye drops containing carmellose sodium 2.5 mg per mL, single dose units 0.6 mL, 24	Application to the eye	TheraTears	CX	AO MP NP	C6172	4	5	1
Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30	Application to the eye	a	Cellufresh	AG	MP NP AO	C6172	3	5	1
a	Optifresh Tears	PP	MP NP AO	C6172	3	5	1
Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30	Application to the eye	a	Celluvisc	AG	MP NP AO	C6172	3	5	1
a	Optifresh Plus	PP	MP NP AO	C6172	3	5	1
Ocular lubricating gel containing carmellose sodium 10 mg per mL, single dose units 0.6 mL, 28	Application to the eye	TheraTears	CX	AO MP NP	C6172	3	5	1

Schedule 1, entry for Cephalexin in the form Capsule 250 mg (anhydrous)
omit:

APO-Cephalexin	TX	MP	P4243	40	2	20
Cefalexin Sandoz	SZ	MP	P4243	40	2	20
Cephalex 250	CR	MP	P4243	40	2	20
Cephalexin AN	EA	MP	P4243	40	2	20
Cephalexin generichealth	GQ	MP	P4243	40	2	20
Chem mart Cephalexin	CH	MP	P4243	40	2	20
Cilex	ED	MP	P4243	40	2	20
Ialex	LN	MP	P4243	40	2	20
Ibilex 250	AF	MP	P4243	40	2	20
Keflex	AS	MP	P4243	40	2	20
Rancef	RA	MP	P4243	40	2	20
Terry White Chemists Cephalexin	TW	MP	P4243	40	2	20

substitute:

a	APO-Cephalexin	TX	MP	P4243	40 CN4243	2 CN4243	20
a	Cefalexin Sandoz	SZ	MP	P4243	40 CN4243	2 CN4243	20
a	Cephalex 250	CR	MP	P4243	40 CN4243	2 CN4243	20
a	Cephalexin AN	EA	MP	P4243	40 CN4243	2 CN4243	20
a	Cephalexin generichealth	GQ	MP	P4243	40 CN4243	2 CN4243	20
a	Chem mart Cephalexin	CH	MP	P4243	40 CN4243	2 CN4243	20
a	Cilex	ED	MP	P4243	40 CN4243	2 CN4243	20
a	Ialex	LN	MP	P4243	40 CN4243	2 CN4243	20
a	Ibilex 250	AF	MP	P4243	40 CN4243	2 CN4243	20
a	Keflex	AS	MP	P4243	40 CN4243	2 CN4243	20
a	Rancef	RA	MP	P4243	40 CN4243	2 CN4243	20
a	Terry White Chemists Cephalexin	TW	MP	P4243	40 CN4243	2 CN4243	20

Schedule 1, after entry for Cephalexin in the form Capsule 500 mg (anhydrous) [Brand: Terry White Chemists Cephalexin; Maximum Quantity: 20; Number of Repeats: 1]
insert in the columns in the order indicated:

a	APO-Cephalexin	TX	MP	P6188	40 CN6188	1 CN6188	20
a	Cefalexin Sandoz	SZ	MP	P6188	40 CN6188	1 CN6188	20
a	Cephalex 500	CR	MP	P6188	40 CN6188	1 CN6188	20
a	Cephalexin AN	EA	MP	P6188	40 CN6188	1 CN6188	20
a	Cephalexin generichealth	GQ	MP	P6188	40 CN6188	1 CN6188	20
a	Chem mart Cephalexin	CH	MP	P6188	40 CN6188	1 CN6188	20
a	Cilex	ED	MP	P6188	40 CN6188	1 CN6188	20
a	Ialex	LN	MP	P6188	40 CN6188	1 CN6188	20
a	Ibilex 500	AF	MP	P6188	40 CN6188	1 CN6188	20
a	Keflex	AS	MP	P6188	40 CN6188	1 CN6188	20
a	Rancef	RA	MP	P6188	40 CN6188	1 CN6188	20
a	Terry White Chemists Cephalexin	TW	MP	P6188	40 CN6188	1 CN6188	20

Schedule 1, entry for Clonazepam
substitute:

Clonazepam	Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)	Injection	Rivotril	RO	MP NP	C1093	5	0	5
Oral liquid 2.5 mg per mL, 10 mL	Oral	Rivotril	RO	MP NP	C1574 C6140	P1574	2	0	1
MP NP	C1574 C6140	P6140	2	3	1
Tablet 500 micrograms	Oral	a	Paxam 0.5	AF	MP NP	C1574 C6140	P6140	100	3	100
a	Rivotril	RO	MP NP	C1574 C6140	P6140	100	3	100
a	Paxam 0.5	AF	MP NP	C1574 C6140	P1574	200	2	100
a	Rivotril	RO	MP NP	C1574 C6140	P1574	200	2	100
Tablet 2 mg	Oral	a	Paxam 2	AF	MP NP	C1574 C6140	P6140	100	3	100
a	Rivotril	RO	MP NP	C1574 C6140	P6140	100	3	100
a	Paxam 2	AF	MP NP	C1574 C6140	P1574	200	2	100
a	Rivotril	RO	MP NP	C1574 C6140	P1574	200	2	100

Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate)
(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Blooms the Chemist Clopidogrel

IB

MP NP

C4165 C4166 C5436 C5459 C5508 C5517 C5524 C5525

28

5

28

(b)insert in numerical order in the column headed “Circumstances” for the brands “Chem mart Clopidogrel” and “Terry White Chemists Clopidogrel”:
C4165 C4166

Schedule 1, entry for Diazepam
substitute:

Diazepam	Tablet 2 mg	Oral	a	Antenex 2	AF	MP NP PDP	50	0	50
a	APO-Diazepam	TX	MP NP PDP	50	0	50
a	Ranzepam	MP NP PDP	50	0	50
a	Valpam 2	RW	MP NP PDP	50	0	50
a	Antenex 2	AF	MP NP	P6176	50 CN6176	3 C6176	50
a	APO-Diazepam	TX	MP NP	P6176	50 CN6176	3 C6176	50
a	Ranzepam	RA	MP NP	P6176	50 CN6176	3 C6176	50
a	Valpam 2	RW	MP NP	P6176	50 CN6176	3 C6176	50
Tablet 5 mg	Oral	a	Antenex 5	AF	MP NP PDP	50	0	50
a	APO-Diazepam	TX	MP NP PDP	50	0	50
a	Ranzepam	RA	MP NP PDP	50	0	50
a	Valium	RO	MP NP PDP	50	0	50
a	Valpam 5	RW	MP NP PDP	50	0	50
a	Antenex 5	AF	MP NP	P6176	50 CN6176	3 CN6176	50
a	APO-Diazepam	TX	MP NP	P6176	50 CN6176	3 CN6176	50
a	Ranzepam	RA	MP NP	P6176	50 CN6176	3 CN6176	50
a	Valium	RO	MP NP	P6176	50 CN6176	3 CN6176	50
a	Valpam 5	RW	MP NP	P6176	50 CN6176	3 CN6176	50
Injection 10 mg in 2 mL	Injection	Hospira Pty Limited	HH	MP NP PDP	5	0	5
Oral liquid 1 mg in 1 mL, 100 mL	Oral	Diazepam Elixir	ON	MP NP	C4244	1	0	1

Schedule 1, entry for Diclofenac
substitute:

Diclofenac	Suppository containing diclofenac sodium 100 mg	Rectal	Voltaren 100	NV	PDP	40	0	20
MP NP MW	P6149	40	3	20
Tablet (enteric coated) containing diclofenac sodium 25 mg	Oral	a	APO-Diclofenac	TX	PDP	C1036 C1054	100	0	50
a	Chem mart Diclofenac	CH	PDP	C1036 C1054	100	0	50
a	Clonac 25	RW	PDP	C1036 C1054	100	0	50
a	Diclofenac AN	EA	PDP	C1036 C1054	100	0	50
a	Diclofenac Sandoz	SZ	PDP	C1036 C1054	100	0	50
a	Diclofenac-GA	ED	PDP	C1036 C1054	100	0	50
a	Fenac 25	AF	PDP	C1036 C1054	100	0	50
a	Terry White Chemists Diclofenac	TW	PDP	C1036 C1054	100	0	50
a	Voltaren 25	NV	PDP	C1036 C1054	100	0	50
a	APO-Diclofenac	TX	MP NP	C1036 C1054 C6149	100	3	50
a	Chem mart Diclofenac	CH	MP NP	C1036 C1054 C6149	100	3	50
a	Clonac 25	RW	MP NP	C1036 C1054 C6149	100	3	50
a	Diclofenac AN	EA	MP NP	C1036 C1054 C6149	100	3	50
a	Diclofenac Sandoz	SZ	MP NP	C1036 C1054 C6149	100	3	50
a	Diclofenac-GA	ED	MP NP	C1036 C1054 C6149	100	3	50
a	Fenac 25	AF	MP NP	C1036 C1054 C6149	100	3	50
a	Terry White Chemists Diclofenac	TW	MP NP	C1036 C1054 C6149	100	3	50
a	Voltaren 25	NV	MP NP	C1036 C1054 C6149	100	3	50
Tablet (enteric coated) containing diclofenac sodium 50 mg	Oral	a	APO-Diclofenac	TX	PDP	C1036 C1054	50	0	50
a	Chem mart Diclofenac	CH	PDP	C1036 C1054	50	0	50
a	Clonac 50	RW	PDP	C1036 C1054	50	0	50
a	Diclofenac AN	EA	PDP	C1036 C1054	50	0	50
a	Diclofenac Sandoz	SZ	PDP	C1036 C1054	50	0	50
a	Diclofenac-GA	ED	PDP	C1036 C1054	50	0	50
a	Fenac	AF	PDP	C1036 C1054	50	0	50
a	Terry White Chemists Diclofenac	TW	PDP	C1036 C1054	50	0	50
a	Voltaren 50	NV	PDP	C1036 C1054	50	0	50
a	APO-Diclofenac	TX	MP NP	C1036 C1054 C6149	50	3	50
a	Chem mart Diclofenac	CH	MP NP	C1036 C1054 C6149	50	3	50
a	Clonac 50	RW	MP NP	C1036 C1054 C6149	50	3	50
a	Diclofenac AN	EA	MP NP	C1036 C1054 C6149	50	3	50
a	Diclofenac Sandoz	SZ	MP NP	C1036 C1054 C6149	50	3	50
a	Diclofenac-GA	ED	MP NP	C1036 C1054 C6149	50	3	50
a	Fenac	AF	MP NP	C1036 C1054 C6149	50	3	50
a	Terry White Chemists Diclofenac	TW	MP NP	C1036 C1054 C6149	50	3	50
a	Voltaren 50	NV	MP NP	C1036 C1054 C6149	50	3	50

Schedule 1, entry for Dicloxacillin
omit:

Capsule 500 mg (as sodium)	Oral	Distaph 500	AF	MP NP MW	C5415	24	0	24
PDP	C5268	24	0	24

substitute:

Capsule 500 mg (as sodium)	Oral	Distaph 500	AF	MP	C5415 C6188	P5415	24	0	24
PDP	C5268	24	0	24
NP MW	C5415	24	0	24
MP	C5415 C6188	P6188	48	1	24

Schedule 1, entry for Diltiazem in each of the forms: Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg; and Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg
(a)omit:

Chem mart Diltiazem CD

CH

MP NP

30

5

30

(b)omit:

GenRx Diltiazem CD

GX

MP NP

30

5

30

(c)omit:

Terry White Chemists Diltiazem CD

TW

MP NP

30

5

30

Schedule 1, entry for Docosahexaenoic acid with carbohydrate
omit from the column headed “Circumstances”: C4434 substitute: C6141
Schedule 1, entry for Donepezil in each of the forms: Tablet containing donepezil hydrochloride 5 mg; and Tablet containing donepezil hydrochloride 10 mg
omit from the column headed “Responsible Person” for the brands “Aridon APN 5” and Aridon APN 10” respectively: FM substitute: RF
Schedule 1, entry for Doxorubicin in the form Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial
omit from the column headed “Responsible Person” for the brand “Doxorubicin MYX”: YN substitute: OC
Schedule 1, after entry for Doxycycline in the form Tablet 100 mg (as monohydrate) [Brand: Terry White Chemists Doxycycline; Maximum Quantity: 28; Number of Repeats: 0; P4514]
insert in the columns in the order indicated:

a	Chem mart Doxycycline	CH	MP	P6200	28	5	7
a	Doxycycline Sandoz	HX	MP	P6200	28	5	7
a	GenRx Doxycycline	GX	MP	P6200	28	5	7
a	Terry White Chemists Doxycycline	TW	MP	P6200	28	5	7

Schedule 1, after entry for Doxycycline in the form Tablet 100 mg (as hydrochloride) [Brand: Doxylin 100; Maximum Quantity: 28; Number of Repeats: 0; P4514]
insert in the columns in the order indicated:

a	Doxsig	RW	MP	P6200	28	5	7
a	Doxy-100	ED	MP	P6200	28	5	7
a	Doxycycline AN	EA	MP	P6200	28	5	7
a	Doxylin 100	AF	MP	P6200	28	5	7

Schedule 1, after entry for Doxycycline in the form Capsule 100 mg (as hydrochloride) (containing enteric coated pellets) [Brand: Mayne Pharma Doxycycline; Maximum Quantity: 28; Number of Repeats: 0; P4514]
insert in the columns in the order indicated:

a	Doryx	YN	MP	P6200	28	5	7
a	Mayne Pharma Doxycycline	YT	MP	P6200	28	5	7

Schedule 1, entry for Dutasteride
omit from the column headed “Circumstances”: C3667 substitute: C6202
Schedule 1, entry for Dutasteride with tamsulosin
omit from the column headed “Circumstances”: C3687 substitute: C6189
Schedule 1, entry for Enoxaparin
omit:

Solution for injection containing enoxaparin sodium 40 mg (4,000 I.U. anti‑Xa) in 0.4 mL	Injection	Clexane	SW	MP NP	20	0	10
MP NP	P4910	20	3	10

Schedule 1, entry for Eplerenone in each of the forms: Tablet 25 mg; and Tablet 50 mg
(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a

Inpler

AF

MP NP

C4937

30

5

30

(b)insert in the column headed “Schedule Equivalent” for the brand “Inspra”: a

Schedule 1, entry for Eribulin
omit from the column headed “Circumstances”: C4646
Schedule 1, after entry for Erythromycin in the form Tablet 400 mg (as ethyl succinate) [Brand: E-Mycin; Maximum Quantity: 25; Number of Repeats: 1]
insert in the columns in the order indicated:

a	E-Mycin	AF	MP	P6160	50 CN6160	5 CN6160	25
a	E.E.S. 400 Filmtab	ZC	MP	P6160	50 CN6160	5 CN6160	25

Schedule 1, after entry for Erythromycin in the form Capsule 250 mg (containing enteric coated pellets) [Brand: Mayne Pharma Erythromycin; Maximum Quantity: 25; Number of Repeats: 1]
insert in the columns in the order indicated:

a	Eryc	YN	MP	P6160	50 CN6160	5 CN6160	25
a	Mayne Pharma Erythromycin	YT	MP	P6160	50 CN6160	5 CN6160	25

Schedule 1, entry for Esomeprazole in each of the forms: Tablet (enteric coated) 20 mg (as magnesium trihydrate); and Tablet (enteric coated) 40 mg (as magnesium trihydrate)
omit from the column headed “Responsible Person” for the brand “Nexole” (all instances): QA substitute: RF
Schedule 1, entry for Fentanyl in each of the forms: Tablet (orally disintegrating) 100 microgram (as citrate); Tablet (orally disintegrating) 200 microgram (as citrate); Tablet (orally disintegrating) 400 microgram (as citrate); Tablet (orally disintegrating) 600 microgram (as citrate); and Tablet (orally disintegrating) 800 microgram (as citrate)
omit from the column headed “Form”: microgram substitute: micrograms

Schedule 1, entry for Flucloxacillin
omit:

Capsule 500 mg (as sodium)	Oral	APO-Flucloxacillin	TX	MP NP MW	C5414	24	0	24
PDP	C5298	24	0	24
Flopen	AS	MP NP MW	C5414	24	0	24
PDP	C5298	24	0	24
Staphylex 250	AF	MP NP MW	C5414	24	0	24
PDP	C5298	24	0	24

substitute:

Capsule 500 mg (as sodium)	Oral	a	APO-Flucloxacillin	TX	MP	C5414 C6169	P5414	24	0	24
NP MW	C5414	24	0	24
PDP	C5298	24	0	24
a	Flopen	AS	MP	C5414 C6169	P5414	24	0	24
NP MW	C5414	24	0	24
PDP	C5298	24	0	24
a	Staphylex 500	AF	MP	C5414 C6169	P5414	24	0	24
NP MW	C5414	24	0	24
PDP	C5298	24	0	24
a	APO-Flucloxacillin	TX	MP	C5414 C6169	P6169	48	1	24
a	Flopen	AS	MP	C5414 C6169	P6169	48	1	24
a	Staphylex 500	AF	MP	C5414 C6169	P6169	48	1	24

Schedule 1, entry for Flucloxacillin in the form Powder for injection 500 mg (as sodium)
omit:

Flucil

AS

MP NP PDP

5

0

5

Schedule 1, entry for Fusidic acid
substitute:

Fusidic acid	Tablet containing sodium fusidate 250 mg	Oral	Fucidin	CS	MP	C4963 C6133	P4963	36	1	36
MP	C4963 C6133	P6133	72	1	36

Schedule 1, entry for Gemfibrozil
(a)omit:

a	Chem mart Gemfibrozil	CH	MP	C6028 C6048	P6048	60	5	60
NP	C6048	60	5	60

(b)omit:

a	GenRx Gemfibrozil	GX	MP	C6028 C6048	P6048	60	5	60
NP	C6048	60	5	60

(c)omit:

a	Terry White Chemists Gemfibrozil	TW	MP	C6028 C6048	P6048	60	5	60
NP	C6048	60	5	60

(d)omit:

a

Chem mart Gemfibrozil

CH

MP

C6028 C6048

P6028

60

11

60

(e)omit:

a

GenRx Gemfibrozil

GX

MP

C6028 C6048

P6028

60

11

60

(f)omit:

a

Terry White Chemists Gemfibrozil

TW

MP

C6028 C6048

P6028

60

11

60

Schedule 1, entry for Glucose Indicator—Blood in each of the forms: Test strips, 50 (Accu-Chek Aviva); and Test strips, 50 (Accu-Chek Go)
omit from the column headed “Responsible Person”: RD substitute: RP
Schedule 1, entry for Glucose Indicator—Blood in each of the forms: Test strips, 100 (Accu-Chek Active); Test strips, 100 (Accu-Chek Mobile); and Test strips, 100 (Accu-Chek Performa)
omit from the column headed “Responsible Person”: RD substitute: RP
Schedule 1, entry for Hyaluronic Acid
substitute:

Hyaluronic acid	Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL	Application to the eye	Hylo-Fresh	AE	AO MP NP	C4105	1	5	1
Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL	Application to the eye	Hylo-Forte	AE	AO MP NP	C4105	1	5	1

Schedule 1, entry for Hyoscine
substitute:

Hyoscine

Injection containing hyoscine butylbromide 20 mg in 1 mL

Injection

Buscopan

BY

MP NP

P6207

30
CN6207

3
CN6207

5

Schedule 1, entry for Hypromellose with Dextran
omit:

Eye drops containing 3 mg hypromellose 2900 with 1 mg dextran 70 per mL, single dose units 0.4 mL, 28	Application to the eye	Bion Tears	AQ	AO	C2802	3	5	1
MP NP	C1359	3	5	1

substitute:

Eye drops containing 3 mg hypromellose 2900 with 1 mg dextran 70 per mL, single dose units 0.4 mL, 28

Application to the eye

Bion Tears

AQ

AO MP NP

C6172

3

5

1

Schedule 1, entry for Ibuprofen
substitute:

Ibuprofen	Tablet 400 mg	Oral	Brufen	GO	MP NP MW PDP	30	0	30
PDP	P1036 P1054	90	0	30
MP NP	P1036 P1054 P6149	90	3	30

Schedule 1, entry for Imatinib in the form Tablet 100 mg (as mesylate) [Maximum Quantity: 60; Number of Repeats: 2]
(a)omit from the column headed “Circumstances”: C4007 C4008
(b)insert in numerical order: C6183 C6184 C6198
Schedule 1, entry for Imatinib in the form Tablet 100 mg (as mesylate) [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”:               C4007 C4008
(b)insert in numerical order:       C6183 C6184 C6198
(c)omit from the column headed “Purposes”:         P4007 P4008
(d)insert in numerical order:       P6183 P6184 P6198

Schedule 1, entry for Imatinib in the form Tablet 400 mg (as mesylate) [Maximum Quantity: 30; Number of Repeats: 2]
(a)omit from the column headed “Circumstances”: C4007 C4008
(b)insert in numerical order: C6183 C6184 C6198
Schedule 1, entry for Imatinib in the form Tablet 400 mg (as mesylate) [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”:               C4007 C4008
(b)insert in numerical order:       C6183 C6184 C6198
(c)omit from the column headed “Purposes”:         P4007 P4008
(d)insert in numerical order:       P6183 P6184 P6198
Schedule 1, entry for Indomethacin
substitute:

Indomethacin	Capsule 25 mg	Oral	a	Arthrexin	AF	PDP	C1036 C1054	100	0	50
a	Indocid	AS	PDP	C1036 C1054	100	0	50
a	Arthrexin	AF	MP NP	C1036 C1054 C6149	100	3	50
a	Indocid	AS	MP NP	C1036 C1054 C6149	100	3	50
Suppository 100 mg	Rectal	Indocid	AS	PDP	40	0	20
MP NP	P6149	40	3	20

Schedule 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL
omit from the column headed “Responsible Person” for the brand “Irinotecan MYX”: YN substitute: OC
Schedule 1, entry for Isosorbide Dinitrate
omit from the column headed “Responsible Person”: QA substitute: RW
Schedule 1, entry for Ketoprofen
omit:

Suppository 100 mg	Rectal	Orudis	SW	PDP	40	0	20
MP NP	40	3	20

Schedule 1, entry for Levodopa with Carbidopa
omit:

Intestinal gel 20 mg‑5 mg per mL, 100 mL	Intra-intestinal	Duodopa	VE	MP	C3704 C3705 C5473	56	5	7
NP	C5473	56	5	7

substitute:

Intestinal gel 20 mg-5 mg per mL, 100 mL	Intra-intestinal	Duodopa	VE	MP NP	C5473	56	5	7
MP	C6154 C6179	56	5	7	C(100)

Schedule 1, entry for Macrogol 3350
substitute:

Macrogol 3350	Powder for oral solution 510 g	Oral	a	OsmoLax	KY	MP NP	C4171 C4173 C4177 C4179 C4180 C6170	P4171 P4173 P4177 P4179 P4180	1	5	1
MP NP	C4171 C4173 C4177 C4179 C4180 C6170	P6170	2	3	1
Sachets containing powder for oral solution 17 g, 30	Oral	a	Herron ClearLax	ON	MP NP	C4171 C4173 C4177 C4179 C4180 C6170	P4171 P4173 P4177 P4179 P4180	1	5	1
MP NP	C4171 C4173 C4177 C4179 C4180 C6170	P6170	2	3	1
Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL	Oral	Movicol Liquid	NE	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1
MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	2	5	1
Sachets containing powder for oral solution 13.125 g with electrolytes, 30	Oral	a	APO-MACROGOL plus ELECTROLYTES	TX	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1
a	Chemists' Own Macrogol with Electrolytes	RW	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1
a	LaxaCon	EA	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1
a	Macrovic	RF	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1
a	Molaxole	HM	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1
a	Movicol	NE	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1
a	lax-sachets	AE	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P4576 P4577 P4580 P4596 P4601	1	5	1
a	APO-MACROGOL plus ELECTROLYTES	TX	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1
a	Chemists' Own Macrogol with Electrolytes	RW	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1
a	LaxaCon	EA	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1
a	Macrovic	RF	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1
a	Molaxole	HM	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1
a	Movicol	NE	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1
a	lax-sachets	AE	MP NP	C4576 C4577 C4580 C4596 C4601 C6171	P6171	2	3	1
a	APO-MACROGOL plus ELECTROLYTES	TX	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
a	Chemists' Own Macrogol with Electrolytes	RW	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
a	LaxaCon	EA	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
a	Macrovic	RF	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
a	Molaxole	HM	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
a	Movicol	NE	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)
a	lax-sachets	AE	MP	See Note 2	See Note 2	See Note 2	See Note 2	1	C(100)

Schedule 1, entry for Methotrexate in each of the forms: Injection 50 mg in 2 mL vial; and Solution concentrate for I.V. infusion 1000 mg in 10 mL vial
omit from the column headed “Responsible Person” for the brand “Methotrexate MYX” (all instances): YN substitute: OC
Schedule 1, after entry for Methylnaltrexone
substitute:

Methylnaltrexone	Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL	Injection	Relistor	LM	MP NP	C6180	7	0	1
MP NP	C6180	7	0	7

Schedule 1, entry for Milk powder—synthetic
omit from the column headed “Circumstances”: C1158 substitute: C6208

Schedule 1, entry for Morphine
(a)omit:

Tablet containing morphine sulfate 10 mg	Oral	Sevredol	MF	MP NP	C4935 C4948 C4960	P4935 P4960	20	0	20
MP NP	C4935 C4948 C4960	P4948	20	2	20
Tablet containing morphine sulfate 20 mg	Oral	Sevredol	MF	MP NP	C4935 C4948 C4960	P4935 P4960	20	0	20
MP NP	C4935 C4948 C4960	P4948	20	2	20

substitute:

Tablet containing morphine sulfate 10 mg	Oral	Sevredol	MF	MP NP	C4960 C6168	P4960	20	0	20
MP NP	C4960 C6168	P6168	20	2	20
Tablet containing morphine sulfate 20 mg	Oral	Sevredol	MF	MP NP	C4960 C6168	P4960	20	0	20
MP NP	C4960 C6168	P6168	20	2	20

(b)omit:

Tablet containing morphine sulfate 200 mg (controlled release)	Oral	MS Contin	MF	MP NP	C4900 C4911 C4927	P4900 P4927	28	0	28
MP NP	C4900 C4911 C4927	P4911	28	2	28

substitute:

Tablet containing morphine sulfate 200 mg (controlled release)	Oral	MS Contin	MF	MP NP	C4900 C6151	P4900	28	0	28
MP NP	C4900 C6151	P6151	28	2	28

Schedule 1, entry for Naloxone
substitute:

Naloxone

Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule

Injection

Naloxone Hydrochloride (DBL)

HH

MP NP PDP

5

0

5

Schedule 1, entry for Naproxen
substitute:

Naproxen	Oral suspension 125 mg per 5 mL, 474 mL	Oral	Phebra Naproxen Suspension	PL	MP NP	C4124 C4159 C6150	1	3	1
Tablet 250 mg	Oral	a	Inza 250	AF	PDP	C1036 C1054	100	0	50
a	Naprosyn	IX	PDP	C1036 C1054	100	0	50
a	Inza 250	AF	MP NP	C1036 C1054 C6149	100	3	50
a	Naprosyn	IX	MP NP	C1036 C1054 C6149	100	3	50
Tablet 500 mg	Oral	a	Inza 500	AF	PDP	C1036 C1054	50	0	50
a	Naprosyn	IX	PDP	C1036 C1054	50	0	50
a	Inza 500	AF	MP NP	C1036 C1054 C6149	50	3	50
a	Naprosyn	IX	MP NP	C1036 C1054 C6149	50	3	50
Tablet containing naproxen sodium 550 mg	Oral	a	Anaprox 550	IX	PDP	C1036 C1054	50	0	50
a	Crysanal	IY	PDP	C1036 C1054	50	0	50
a	Anaprox 550	IX	MP NP	C1036 C1054 C6196	50	3	50
a	Crysanal	IY	MP NP	C1036 C1054 C6196	50	3	50
Tablet 750 mg (sustained release)	Oral	a	Naprosyn SR750	IX	PDP	C1036 C1054	28	0	28
a	Proxen SR 750	IY	PDP	C1036 C1054	28	0	28
a	Naprosyn SR750	IX	MP NP	C1036 C1054 C6149	28	3	28
a	Proxen SR 750	IY	MP NP	C1036 C1054 C6149	28	3	28
Tablet 1 g (sustained release)	Oral	a	Naprosyn SR1000	IX	PDP	C1036 C1054	28	0	28
a	Proxen SR 1000	IY	PDP	C1036 C1054	28	0	28
a	Naprosyn SR1000	IX	MP NP	C1036 C1054 C6149	28	3	28
a	Proxen SR 1000	IY	MP NP	C1036 C1054 C6149	28	3	28

Schedule 1, entry for Nitrazepam in the form Tablet 5 mg
omit:

Alodorm	AF	MP NP	P5610	50 CN5610	0	25
Mogadon	IA	MP NP	P5610	50 CN5610	0	25

Schedule 1, entry for Nitrazepam in the form Tablet 5 mg [Maximum Quantity: 50; Number of Repeats: 3]
(a)omit from the column headed “Purposes” (twice occurring):         P5662    substitute:             P6175
(b)omit from the column headed “Maximum Quantity” (twice occurring):       CN5662 substitute:             CN6175
(c)omit from the column headed “Number of Repeats” (twice occurring):       CN5662 substitute:             CN6175
Schedule 1, entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg [Maximum Quantity: 4; Number of Repeats: 0]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Ondansetron ODT GH	GQ	MP NP	C5618 C5777	P5618	4	0	4
MP	C5743	4	0	4	C(100)

Schedule 1, entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg [Maximum Quantity: 10; Number of Repeats: 1]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Ondansetron ODT GH

GQ

MP NP

C5618 C5777

P5777

10

1

10

Schedule 1, entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg [Maximum Quantity: 4; Number of Repeats: 0]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Ondansetron ODT GH	GQ	MP NP	C5618 C5777	P5618	4	0	4
MP	C5743	4	0	4	C(100)

Schedule 1, entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg [Maximum Quantity: 10; Number of Repeats: 1]
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Ondansetron ODT GH

GQ

MP NP

C5618 C5777

P5777

10

1

10

Schedule 1, entry for Oxazepam in the form Tablet 15 mg
omit:

Alepam 15	AF	MP NP	P3656	50 CN3656	0	25
Serepax	QA	MP NP	P3656	50 CN3656	0	25

Schedule 1, entry for Oxazepam in the form Tablet 15 mg [Maximum Quantity: 50; Number of Repeats: 3]
(a)omit from the column headed “Purposes” (twice occurring):         P3655    substitute:             P6176
(b)omit from the column headed “Maximum Quantity” (twice occurring):       CN3655 substitute:             CN6176
(c)omit from the column headed “Number of Repeats” (twice occurring):       CN3655 substitute:             CN6176
Schedule 1, entry for Oxazepam in the form Tablet 30 mg
omit:

Alepam 30	AF	MP NP	P3656	50 CN3656	25
APO‑Oxazepam	TX	MP NP	P3656	50 CN3656	25
Murelax	RW	MP NP	P3656	50 CN3656	25
Serepax	QA	MP NP	P3656	50 CN3656	25

Schedule 1, entry for Oxazepam in the form Tablet 30 mg [Maximum Quantity: 50; Number of Repeats: 3]
(a)omit from the column headed “Purposes” (all instances):               P3655    substitute:             P6176
(b)omit from the column headed “Maximum Quantity” (all instances):             CN3655 substitute:             CN6176
(c)omit from the column headed “Number of Repeats” (all instances):             CN3655 substitute:             CN6176
Schedule 1, entry for Paracetamol
(a)omit:

Suppositories 500 mg, 24	Rectal	Panadol	GC	MP NP	C4940 C4950	P4950	4	0	1
MP NP	C4940 C4950	P4940	4	3	1

substitute:

Suppositories 500 mg, 24

Rectal

Panadol

GC

MP NP

C6167

4

3

1

(b)omit:

Tablet 665 mg (modified release)	Oral	Osteomol 665 Paracetamol	CR	MP NP	C4940 C4950 C5847	P4950	192	0	96
MP NP	C4940 C4950 C5847	P4940	192	3	96
MP NP	C4940 C4950 C5847	P5847	192	5	96

substitute:

Tablet 665 mg (modified release)	Oral	Osteomol 665 Paracetamol	CR	MP NP	C5847 C6167	P6167	192	3	96
MP NP	C5847 C6167	P5847	192	5	96

Schedule 1, entry for Pemetrexed in each of the forms: Powder for I.V. infusion 100 mg (as disodium); and Powder for I.V. infusion 500 mg (as disodium)
omit from the column headed “Responsible Person” for the brand “Pemetrexed MYX”: YN substitute: OC
Schedule 1, entry for Phenoxybenzamine in each of the forms: Capsule containing phenoxybenzamine hydrochloride 10 mg; Capsule containing 10 mg phenoxybenzamine hydrochloride; and Capsules containing phenoxybenzamine hydrochloride 10 mg, 30
omit from the column headed “Circumstances”: C4772 C4781 substitute: C6145 C6178
Schedule 1, entry for Polyethylene Glycol 400 with Propylene Glycol
omit:

Eye drops 4 mg‑3 mg per mL, single dose units 0.8 mL, 28	Application to the eye	Systane	AQ	MP NP	C1359	2	5	1
AO	C2802	2	5	1

substitute:

Eye drops 4 mg-3 mg per mL, single dose units 0.8 mL, 28

Application to the eye

Systane

AQ

AO MP NP

C6172

2

5

1

Schedule 1, entry for Protein hydrolysate formula with medium chain triglycerides
substitute:

Protein hydrolysate formula with medium chain triglycerides	Oral powder 400 g (Alfaré)	Oral	Alfaré	NT	MP NP	C6137 C6138 C6148 C6157 C6158 C6166 C6174 C6182 C6193 C6194 C6195 C6204 C6205 C6206	8	5	1
Oral powder 450 g (Aptamil Gold+ Pepti-Junior)	Oral	Aptamil Gold+ Pepti-Junior	NU	MP NP	C6137 C6138 C6148 C6157 C6158 C6166 C6174 C6182 C6193 C6194 C6195 C6204 C6205	8	5	1

Schedule 1, entry for Quetiapine in each of the forms: Tablet (modified release) 200 mg (as fumarate); Tablet (modified release) 300 mg (as fumarate); and Tablet (modified release) 400 mg (as fumarate)
(a)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a

QUETIAPINE-AS XR

RW

MP NP

C4246 C5611 C5639

60

5

60

(b)insert in the column headed “Schedule Equivalent” for the brand “Seroquel XR”: a

Schedule 1, entry for Risedronic Acid in the form Tablet containing risedronate sodium 150 mg
(a)insert in the column headed “Schedule Equivalent” for all brands: a
(b)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

a

ATELVIA ONCE-A-MONTH

GN

MP NP

C4882 C4885 C4889

1

5

1

Schedule 1, entry for Rituximab in each of the forms: Solution for I.V. infusion 100 mg in 10 mL; and Solution for I.V. infusion 500 mg
in 50 mL
(a)omit from the column headed “Circumstances”:               C5980
(b)omit from the column headed “Circumstances”:               C6001
(c)omit from the column headed “Circumstances”:               C6040 C6058
(d)insert in numerical order:       C6161 C6162 C6187
Schedule 1, entry for Rituximab
omit:

Solution for subcutaneous injection containing rituximab 1400 mg in 11.7 mL	Injection	Mabthera SC	RO	MP	C5980 C5992 C5998 C6011	P5998	1	2	1
MP	C6004 C6008 C6039 C6040	P6039	1	2	1	C(100)
MP	C5980 C5992 C5998 C6011	P5980	1	6	1
MP	C6004 C6008 C6039 C6040	P6040	1	6	1	C(100)
MP	C5980 C5992 C5998 C6011	P6011	1	7	1
MP	C6004 C6008 C6039 C6040	P6008	1	7	1	C(100)
MP	C5980 C5992 C5998 C6011	P5992	1	11	1
MP	C6004 C6008 C6039 C6040	P6004	1	11	1	C(100)

substitute:

Solution for subcutaneous injection containing rituximab 1400 mg in 11.7 mL	Injection	Mabthera SC	RO	MP	C5998 C6011 C6039 C6161 C6162 C6187	P5998 P6039	1	2	1
MP	C5998 C6011 C6039 C6161 C6162 C6187	P6162 P6187	1	6	1
MP	C5998 C6011 C6039 C6161 C6162 C6187	P6011	1	7	1
MP	C5998 C6008 C6039 C6161 C6162 C6187	P6008	1	7	1	C(100)
MP	C5998 C6011 C6039 C6161 C6162 C6187	P6161	1	11	1

Schedule 1, entry for Salbutamol in the form Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)
omit:

APO‑Salbutamol Inhaler

TX

MP NP

2

5

1

Schedule 1, entry for Sorbitol with sodium citrate and sodium lauryl sulfoacetate in the form Enemas 3.125 g-450 mg-45 mg in 5 mL, 12
omit:

a	Micolette	AE	MP NP	C5613 C5640 C5641 C5685 C5720 C5774 C5775 C5776 C5804	P5641	2	0	1
a	Microlax	JT	MP NP	C5613 C5640 C5641 C5685 C5720 C5774 C5775 C5776 C5804	P5641	2	0	1

Schedule 1, entry for Sorbitol with sodium citrate and sodium lauryl sulfoacetate in the form Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 [Maximum Quantity: 2; Number of Repeats: 2]
(a)omit from the column headed “Circumstances” (twice occurring):               C5641
(b)omit from the column headed “Circumstances” (twice occurring):               C5774
(c)insert in numerical order:       C6139
Schedule 1, entry for Sorbitol with sodium citrate and sodium lauryl sulfoacetate in the form Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 [Maximum Quantity: 2; Number of Repeats: 3]
(a)omit from the column headed “Circumstances” (twice occurring):               C5641
(b)omit from the column headed “Circumstances” (twice occurring :               C5774
(c)insert in numerical order:       C6139
(d)omit from the column headed “Purposes” (twice occurring):         P5774   substitute:             P6139
Schedule 1, entry for Soy lethicin
substitute:

Soy lecithin

Eye spray 10 mg per mL, 10 mL

Application

tearsagain

RB

AO MP NP

C6172

2

5

1

Schedule 1, entry for Sterculia with frangula bark in the form Granules 620 mg-80 mg per g, 500 g
omit:

MP NP

C5613 C5640 C5641 C5685 C5720 C5774 C5775 C5776 C5804

P5641

1

0

1

Schedule 1, entry for Sterculia with frangula bark in the form Granules 620 mg-80 mg per g, 500 g [Maximum Quantity: 1; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”:               C5641
(b)omit from the column headed “Circumstances”:               C5774
(c)insert in numerical order:       C6139
Schedule 1, entry for Sterculia with frangula bark in the form Granules 620 mg-80 mg per g, 500 g [Maximum Quantity: 1; Number of Repeats: 3]
(a)omit from the column headed “Circumstances”:               C5641
(b)omit from the column headed “Circumstances”:               C5774
(c)insert in numerical order:       C6139
(d)omit from the column headed “Purposes”:         P5774   substitute:             P6139
Schedule 1, entry for Temazepam
omit:

APO‑Temazepam	TX	MP NP	P5610	50 CN5610	25
Normison	QA	MP NP	P5610	50 CN5610	25
Temaze	AF	MP NP	P5610	50 CN5610	25
Temtabs	FM	MP NP	P5610	50 CN5610	25

Schedule 1, entry for Temazepam in the form Tablet 10 mg [Maximum Quantity: 50; Number of Repeats: 3]
(a)omit from the column headed “Purposes” (all instances):               P5662    substitute:             P6175
(b)omit from the column headed “Maximum Quantity” (all instances):             CN5662 substitute:             CN6175
(c)omit from the column headed “Number of Repeats” (all instances):             CN5662 substitute:             CN6175
Schedule 1, entry for Tiotropium in the form Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 doses)
omit from the column headed “Authorised Prescriber”: MP substitute: MP NP
Schedule 1, entry for Tramadol in the form Capsule containing tramadol hydrochloride 50 mg
omit from the column headed “Responsible Person” for the brand “Zydol” (twice occurring): QA substitute: RW

Schedule 1, entry for Tramadol in each of the forms: Tablet (sustained release) containing tramadol hydrochloride 100 mg; Tablet (sustained release) containing tramadol hydrochloride 150 mg; and Tablet (sustained release) containing tramadol hydrochloride 200 mg
omit from the column headed “Responsible Person” for the brands “Zydol SR 100”, “Zydol SR 150” and “Zydol SR 200” respectively: QA
substitute: RW
Schedule 1, entry for Triglycerides, medium chain in each of the forms: Oil 500 mL (MCT Oil); and Oral emulsion 250 mL (Liquigen)
omit from the column headed “Circumstances”: C4379 C4393 C5690 C5723 C5807 C5853 C5888
substitute: C6134 C6135 C6146 C6155 C6164 C6181 C6203
Schedule 1, entry for Triglycerides, medium chain in the form Oral liquid 250 mL, 18 (betaquik)
omit from the column headed “Circumstances”: C4443 C4447 substitute: C6147 C6191
Schedule 1, entry for Triglycerides—medium chain, formula in the Sachets containing oral powder 16 g, 30 (MCT Pro-Cal)
omit from the column headed “Circumstances”: C5644 C5645 C5693 C5726 C5784 substitute: C6136 C6156 C6165 C6173 C6192
Schedule 1, entry for Trimethoprim
substitute:

Trimethoprim	Tablet 300 mg	Oral	a	Alprim	AF	MP NP	7	1	7
a	Triprim	RW	MP NP	7	1	7
a	Alprim	AF	MP	P4243	14 CN4243	2 CN4243	7
a	Triprim	RW	MP	P4243	14 CN4243	2 CN4243	7
a	Alprim	AF	MP	P6163	28	0	7
a	Triprim	RW	MP	P6163	28	0	7

Schedule 1, entry for Trimethoprim with sulfamethoxazole
omit:

Tablet 160 mg‑800 mg	Oral	Bactrim DS	RO	PDP	10	0	10
Resprim Forte	AF	PDP	10	0	10
Septrin Forte	RW	PDP	10	0	10
Bactrim DS	RO	MP NP	10	1	10
Resprim Forte	AF	MP NP	10	1	10
Septrin Forte	RW	MP NP	10	1	10

substitute:

Tablet 160 mg-800 mg	Oral	a	Bactrim DS	RO	PDP	10	0	10
a	Resprim Forte	AF	PDP	10	0	10
a	Septrin Forte	RW	PDP	10	0	10
a	Bactrim DS	RO	MP NP	10	1	10
a	Resprim Forte	AF	MP NP	10	1	10
a	Septrin Forte	RW	MP NP	10	1	10
a	Bactrim DS	RO	MP	P6201	30 CN6201	2 CN6201	10
a	Resprim Forte	AF	MP	P6201	30 CN6201	2 CN6201	10
a	Septrin Forte	RW	MP	P6201	30 CN6201	2 CN6201	10

Schedule 1, entry for Vitamins, minerals and trace elements with carbohydrate in the form Oral powder 200 g (Paediatric Seravit)
omit from the column headed “Circumstances”: C4916 substitute: C6152
Schedule 1, entry for Vitamins, minerals and trace elements with carbohydrate in the form Sachets containing oral powder 6 g, 30 (FruitiVits)
omit from the column headed “Circumstances”: C4663 substitute: C6159
Schedule 1, entry for Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose in each of the forms: Sachets containing oral powder 100 g, 10 (RenaStart); and Oral powder 400 g, 6 (Renastart)
omit from the column headed “Circumstances”: C4322 substitute: C6190
Schedule 1, entry for Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose
omit from the column headed “Circumstances”: C4322 substitute: C6190

Schedule 3, after details relevant to Responsible Person code OA
insert:

OC

Accord Healthcare Pty Ltd

49 110 502 513

Schedule 3, after details relevant to Responsible Person code RO
insert:

RP

Roche Diabetes Care Australia Pty Ltd

69 602 140 278

Schedule 4, Part 1, entry for Arachidonic acid and docosahexaenoic acid with carbohydrate
substitute:

Arachidonic acid and docosahexaenoic acid with carbohydrate

C6141

Peroxisomal biogenesis disorders

Schedule 4, Part 1, entry for Benzydamine
(a)omit:

C5622

P5622

Painful mouth

Initial treatment

Patient must be receiving palliative care; AND
Patient must not receive more than 4 months treatment under this restriction.

Compliance with Authority Required procedures - Streamlined Authority Code 5622

C5651

P5651

Painful mouth

Continuing treatment

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 5651

(b)insert in numerical order after existing text:

C6197

P6197

Painful mouth

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 6197

Schedule 4, Part 1, entry for Bisacodyl
(a)omit:

C5641

P5641

Constipation

Continuing treatment

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 5641

(b)omit:

C5774

P5774

Constipation

Initial treatment, for up to 4 months

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 5774

(c)insert in numerical order after existing text:

C6139

P6139

Constipation

Patient must be receiving palliative care.

Schedule 4, Part 1, entry for Carbomer
substitute:

Carbomer

C6153

P6153

Severe dry eye syndrome, including Sjogren's syndrome

C6172

Severe dry eye syndrome
Patient must be sensitive to preservatives in multi-dose eye drops.

Compliance with Authority Required procedures - Streamlined Authority Code 6172

C6185

P6185

Severe dry eye syndrome, including Sjogren's syndrome

Patient must be receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements.

Schedule 4, Part 1, entry for Carbomer 974
substitute:

Carbomer 974

C6172

Severe dry eye syndrome
Patient must be sensitive to preservatives in multi-dose eye drops.

Compliance with Authority Required procedures - Streamlined Authority Code 6172

Schedule 4, Part 1, entry for Carmellose
(a)omit:

C1359

Severe dry eye syndrome in patients who are sensitive to preservatives in multi‑dose eye drops

Compliance with Authority Required procedures – Streamlined Authority Code 1359

(b)omit:

C2802

Severe dry eye syndrome in patients who are sensitive to preservatives in multi‑dose eye drops

Compliance with Authority Required procedures

(c)insert in numerical order after existing text

C6172

Severe dry eye syndrome

Patient must be sensitive to preservatives in multi-dose eye drops.

Compliance with Authority Required procedures - Streamlined Authority Code 6172

Schedule 4, Part 1, entry for Cephalexin
(a)insert in the column headed “Conditions Code” for Purposes Code P4243: CN4243
(b)insert in numerical order after existing text:

P6188

CN6188

Osteomyelitis

Compliance with Authority Required procedures - Streamlined Authority Code 6188

Schedule 4, Part 1, entry for Clonazepam
(a)omit:

C3657	P3657	Initial supply, for up to 4 months, for a palliative care patient for the prevention of epilepsy	Compliance with Authority Required procedures
C3658	P3658	Continuing supply for a palliative care patient for the prevention of epilepsy	Compliance with Authority Required procedures

(b)insert in numerical order after existing text:

C6140

P6140

Myoclonus

The treatment must be for prophylaxis or prevention of the indication; AND
Patient must be receiving palliative care.

Compliance with Authority Required procedures

Schedule 4, Part 1, entry for Diazepam
(a)omit:

P3655	CN3655	Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem	Compliance with Authority Required procedures
P3656	CN3656	Continuing supply for a palliative care patient where anxiety is a problem	Compliance with Authority Required procedures

(b)insert in numerical order after existing text:

P6176

CN6176

Anxiety

Patient must be receiving palliative care.

Compliance with Authority Required procedures

Schedule 4, Part 1, entry for Diclofenac
(a)omit from the column headed “Purposes Code” for Circumstances Code C1036: P1036
(b)omit from the column headed “Purposes Code” for Circumstances Code C1054: P1054
(c)omit:

C3645	P3645	Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures – Streamlined Authority Code 3645
C3646	P3646	Continuing supply for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures – Streamlined Authority Code 3646
P3665	CN3665	Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures
P3666	CN3666	Continuing supply for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures

(d)insert in numerical order after existing text:

C6149

P6149

Severe pain

Patient must be receiving palliative care.

Schedule 4, Part 1, entry for Dicloxacillin
(a)insert in the column headed “Purposes Code” for Circumstances Code C5415: P5415
(b)insert in numerical order after existing text:

C6188

P6188

Osteomyelitis

Compliance with Authority Required procedures - Streamlined Authority Code 6188

Schedule 4, Part 1, entry for Docosahexaenoic acid with carbohydrate
substitute:

Docosahexaenoic acid with carbohydrate

C6141

Peroxisomal biogenesis disorders

Schedule 4, Part 1, entry for Doxycycline
insert in numerical order after existing text:

P6200

Severe acne

Schedule 4, Part 1, entry for Dutasteride
substitute:

Dutasteride

C6202

Benign prostatic hyperplasia

Patient must have lower urinary tract symptoms; AND
Patient must have moderate to severe benign prostatic hyperplasia; AND
The treatment must be in combination with an alpha-antagonist.

Compliance with Authority Required procedures - Streamlined Authority Code 6202

Schedule 4, Part 1, entry for Dutasteride with tamsulosin
substitute:

Dutasteride with tamsulosin

C6189

Benign prostatic hyperplasia

Patient must have lower urinary tract symptoms; AND
Patient must have moderate to severe benign prostatic hyperplasia.

Compliance with Authority Required procedures - Streamlined Authority Code 6189

Schedule 4, Part 1, entry for Eribulin
(a)omit:

C4646

Where the patient is receiving treatment in the community setting or at/from a Private Hospital

Locally advanced or metastatic breast cancer

Patient must have progressive disease; AND
Patient must have failed at least two prior chemotherapeutic regimens for this condition; AND
The treatment must be the sole PBS-subsidised therapy for this condition

Compliance with Authority Required procedures

(b)omit from the column headed “Circumstances and Purposes” for Circumstances Code C4649:
Where the patient is receiving treatment at/from a Public Hospital

Schedule 4, Part 1, after entry for Erlotinib
insert:

Erythromycin

P6160

CN6160

Severe acne

The condition must be one in which tetracycline therapy is inappropriate.

Compliance with Authority Required procedures - Streamlined Authority Code 6160

Schedule 4, Part 1, entry for Flucloxacillin
insert in numerical order after existing text:

C6169

P6169

Osteomyelitis

Compliance with Authority Required procedures - Streamlined Authority Code 6169

Schedule 4, Part 1, entry for Fusidic acid
substitute:

Fusidic acid	C4963	P4963	Serious staphylococcal infections The treatment must be used in combination with another antibiotic; AND The condition must be proven to be due to a staphylococcus.
C6133	P6133	Osteomyelitis The condition must be methicillin-resistant staphylococcal aureus (MRSA); AND The treatment must be used in combination with other anti-staphylococcal antibiotics.	Compliance with Authority Required procedures - Streamlined Authority Code 6133

Schedule 4, Part 1, entry for Hyaluronic acid
omit:

C4130

Severe dry eye syndrome

Patient must be sensitive to preservatives in multi‑dose eye drops.

Compliance with Authority Required procedures

Schedule 4, Part 1, entry for Hyoscine
substitute:

Hyoscine

P6207

CN6207

For use in patients receiving palliative care

Compliance with Authority Required procedures - Streamlined Authority Code 6207

Schedule 4, Part 1, entry for Hypromellose with Dextran
(a)omit:

C1359	Severe dry eye syndrome in patients who are sensitive to preservatives in multi‑dose eye drops	Compliance with Authority Required procedures – Streamlined Authority Code 1359
C2802	Severe dry eye syndrome in patients who are sensitive to preservatives in multi‑dose eye drops	Compliance with Authority Required procedures

(b)insert in numerical order after existing text:

C6172

Severe dry eye syndrome

Patient must be sensitive to preservatives in multi-dose eye drops.

Compliance with Authority Required procedures - Streamlined Authority Code 6172

Schedule 4, Part 1, entry for Ibuprofen
(a)omit:

P3665	Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures
P3666	Continuing supply for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures

(b)insert in numerical order after existing text:

P6149

Severe pain

Patient must be receiving palliative care.

Schedule 4, Part 1, entry for Imatinib
(a)omit:

C4007

P4007

Chronic myeloid leukaemia (chronic phase)
Initial treatment, as the sole PBS‑subsidised therapy, of a patient in the chronic phase of chronic myeloid leukaemia expressing the Philadelphia chromosome or the transcript, BCR‑ABL tyrosine kinase, and who has a primary diagnosis of chronic myeloid leukaemia

Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved

Patients should be commenced on a dose of imatinib mesylate of 400 mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to imatinib mesylate therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter

Applications for authorisation must be in writing and must include:
(1) a completed authority prescription form; and
(2) a completed Chronic Myeloid Leukaemia ‑ Chronic Phase, First Line ‑ Supporting Information form; and
(3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR‑ABL transcript in either peripheral blood or bone marrow; and
(4) a signed patient acknowledgement form

Compliance with Written Authority Required procedures

C4008

P4008

Chronic myeloid leukaemia (chronic phase)
Continuing treatment, as the sole PBS‑subsidised therapy, of a patient who has received initial PBS‑subsidised treatment with imatinib mesylate for the chronic phase of chronic myeloid leukaemia and who has demonstrated either a major cytogenetic response or less than 1% BCR‑ABL level in the blood

First continuing applications for authorisation must be in writing and must include:

(1) a completed authority prescription form; and
(2) demonstration of a response to treatment as evidenced by either:
(a) major cytogenetic response; or
(b) a peripheral blood level of BCR‑ABL of less than 1% on the international scale

Definitions of response
A major cytogenetic response is defined as less than 35% Philadelphia positive bone marrow cells
A peripheral blood BCR‑ABL level of less than 1% on the international scale (Blood 108: 28‑37, 2006) also indicates a response, at least the biological equivalent of a major cytogenetic response

Compliance with Written Authority Required procedures

Continuing treatment, as the sole PBS‑subsidised therapy, of a patient who has previously been issued with an authority prescription for continuing treatment with imatinib mesylate for the chronic phase of chronic myeloid leukaemia. Patients must maintain a major cytogenetic response or have a peripheral blood BCR‑ABL of less than 1% to receive continuing therapy

Compliance with Written or Telephone Authority Required procedures

(b)insert in numerical order after existing text:

C6183

P6183

Chronic Myeloid Leukaemia (CML)

Initial

Patient must have a primary diagnosis of chronic myeloid leukaemia; AND
The condition must be in the chronic phase of chronic myeloid leukaemia; AND
The condition must be expressing the Philadelphia chromosome; OR
The condition must have the transcript BCR-ABL tyrosine kinase; AND
The treatment must be for first line therapy for this condition; AND
Patient must not have previously experienced a failure of response to the PBS-subsidised treatment with this drug for this condition; OR
Patient must have experienced intolerance, not a failure of response, to PBS-subsidised treatment with dasatinib as a first line therapy for this condition; OR
Patient must have experienced intolerance, not a failure of response, to PBS-subsidised treatment with nilotinib as a first line therapy for this condition; AND
The treatment must not exceed a total maximum of 18 months of therapy with a PBS-subsidised treatment with a tyrosine kinase inhibitor for this condition; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
Applications for authorisation must be in writing and must include:(1) a completed authority prescription form; and(2) a completed Chronic Myeloid Leukaemia - Chronic Phase, First Line - Supporting Information form; and(3) a pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of chronic myeloid leukaemia to confirm eligibility for treatment, or a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow; and(4) a signed patient acknowledgement form
Applications under this restriction will be limited to provide patients with a maximum of 18 months of therapy with dasatinib, imatinib or nilotinib from the date the first application for initial treatment was approved.
Patients should be commenced on a dose of imatinib mesylate of 400 mg (base) daily. Continuing therapy is dependent on patients demonstrating a response to imatinib mesylate therapy following the initial 18 months of treatment and at 12 monthly intervals thereafter.

Compliance with Written Authority Required procedures

C6184

P6184

Chronic Myeloid Leukaemia (CML)

First Continuing

The condition must be in the chronic phase of chronic myeloid leukaemia; AND
Patient must have received initial PBS-subsidised treatment with this drug as a first line therapy for this condition; OR
Patient must have experienced intolerance, not a failure of response, to PBS-subsidised treatment with dasatinib as a first line therapy for this condition; OR
Patient must have experienced intolerance, not a failure of response, to PBS-subsidised treatment with nilotinib as a first line therapy for this condition; AND
Patient must have demonstrated a major cytogenic response; OR
Patient must have demonstrated a peripheral blood level of BCR-ABL of less than 1%; AND
The treatment must not exceed a total maximum of 24 weeks of therapy with a PBS-subsidised treatment with a tyrosine kinase inhibitor for this condition under this restriction; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
First continuing applications for authorisation must be in writing and must include:
(1) a completed authority prescription form; and
(2) a response to treatment as evidenced by either:
(a) a major cytogenetic response [see Note explaining requirements]; or
(b) a peripheral blood level of BCR-ABL of less than 1% on the international scale [see Note explaining requirements].

Compliance with Written Authority Required procedures

C6198

P6198

Chronic Myeloid Leukaemia (CML)

Subsequent continuing

The condition must be in the chronic phase of chronic myeloid leukaemia; AND
Patient must have received initial continuing PBS-subsidised treatment with this drug as a first line therapy for this condition; OR
Patient must have experienced intolerance, not a failure of response, to PBS-subsidised treatment with dasatinib as a first line therapy for this condition; OR
Patient must have experienced intolerance, not a failure of response, to PBS-subsidised treatment with nilotinib as a first line therapy for this condition; AND
Patient must have maintained a major cytogenic response; OR
Patient must have maintained a peripheral blood level of BCR-ABL of less than 1%; AND
The treatment must not exceed a total maximum of 24 weeks of therapy with a PBS-subsidised treatment with a tyrosine kinase inhibitor for this condition under this restriction; AND
The treatment must be the sole PBS-subsidised therapy for this condition.
Second and subsequent authority applications for continuing therapy with imatinib mesylate may be made on the telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).

Compliance with Authority Required procedures

Schedule 4, Part 1, entry for Indomethacin
(a)omit:

C3645	P3645	Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures – Streamlined Authority Code 3645
C3646	P3646	Continuing supply for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures – Streamlined Authority Code 3646
P3665	CN3665	Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures
P3666	CN3666	Continuing supply for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures

(b)insert in numerical order after existing text:

C6149

P6149

Severe pain

Patient must be receiving palliative care.

Schedule 4, Part 1, entry for Levodopa with Carbidopa
(a)omit:

C3704

Where the patient is receiving treatment at/from a public hospital

Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy.
Treatment must be commenced in a hospital‑based movement disorder clinic

Compliance with Written or Telephone Authority Required procedures – Streamlined Authority Code 3704

C3705

Where the patient is receiving treatment at/from a private hospital

Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy.
Treatment must be commenced in a hospital‑based movement disorder clinic

Compliance with Written or Telephone Authority Required procedures

(b)insert in numerical order after existing text:

C6154

Where the patient is receiving treatment at/from a private hospital

Advanced Parkinson disease

Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND
The treatment must be commenced in a hospital-based movement disorder clinic.

Compliance with Authority Required procedures

C6179

Where the patient is receiving treatment at/from a public hospital

Advanced Parkinson disease

Patient must have severe disabling motor fluctuations not adequately controlled by oral therapy; AND
The treatment must be commenced in a hospital-based movement disorder clinic.

Compliance with Authority Required procedures - Streamlined Authority Code 6179

Schedule 4, Part 1, entry for Macrogol 3350
(a)omit:

C4170

P4170

Constipation
Continuing treatment

Patient must be receiving palliative care

Compliance with Authority Required procedures – Streamlined Authority Code 4170

(b)omit:

C4176

P4176

Constipation
Initial treatment

Patient must be receiving palliative care;

Patient must not receive more than 4 months treatment under this restriction

Compliance with Authority Required procedures – Streamlined Authority Code 4176

(c)omit:

C4590

P4590

Constipation
Continuing treatment
Patient must be receiving palliative care

Compliance with Authority Required procedures - Streamlined Authority Code 4590

C4595

P4595

Constipation

Initial treatment

Patient must be receiving palliative care; AND
Patient must not receive more than 4 months treatment under this restriction

Compliance with Authority Required procedures - Streamlined Authority Code 4595

(d)insert in numerical order after existing text:

C6170

P6170

Constipation

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 6170

C6171

P6171

Constipation

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 6171

Schedule 4, Part 1, entry for Methylnaltrexone
substitute:

Methylnaltrexone

C6180

Opioid-induced constipation

The treatment must be in combination with oral laxatives; AND
Patient must be receiving palliative care; AND
Patient must have failed to respond to laxatives.

Compliance with Authority Required procedures - Streamlined Authority Code 6180

Schedule 4, Part 1, entry for Milk powder — synthetic
substitute:

Milk powder -- synthetic

C6208

Hypercalcaemia

Patient must be under the age of 4 years.

Schedule 4, Part 1, entry for Morphine
(a)omit:

C4911

P4911

Chronic severe disabling pain

Initial treatment, for up to 3 months

Patient must be receiving palliative care; AND
The condition must be unresponsive to non-opioid analgesics

Compliance with Authority Required procedures

(b)omit:

C4927

P4927

Chronic severe disabling pain

Continuing treatment

Patient must be receiving palliative care; AND
The condition must be unresponsive to non-opioid analgesics

Compliance with Authority Required procedures

C4935

P4935

Severe disabling pain

Continuing treatment

Patient must be receiving palliative care; AND
The condition must be unresponsive to non-opioid analgesics

Compliance with Authority Required procedures

C4948

P4948

Severe disabling pain

Initial treatment, for up to 3 months

Patient must be receiving palliative care; AND
The condition must be unresponsive to non-opioid analgesics

Compliance with Authority Required procedures

(c)insert in numerical order after existing text:

C6151

P6151

Chronic severe disabling pain

Patient must be receiving palliative care; AND
The condition must be unresponsive to non-opioid analgesics.

Compliance with Authority Required procedures

C6168

P6168

Severe disabling pain

Patient must be receiving palliative care; AND
The condition must be unresponsive to non-opioid analgesics.

Compliance with Authority Required procedures

Schedule 4, Part 1, entry for Naproxen
(a)omit from the column headed “Purposes Code” for Circumstances Code C1036: P1036
(b)omit from the column headed “Purposes Code” for Circumstances Code C1054: P1054
(c)omit:

C3645	P3645	Initial supply, for up to 4 months, for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures – Streamlined Authority Code 3645
C3646	P3646	Continuing supply for a palliative care patient where severe pain is a problem	Compliance with Authority Required procedures – Streamlined Authority Code 3646

(d)omit from the column headed “Purposes Code” for Circumstances Code C4124: P4124
(e)omit:

C4128

P4128

Severe pain

Initial treatment

Patient must be undergoing palliative care;

Patient must be unable to take a solid dose form of a non‑steroidal anti‑inflammatory agent;

Patient must not receive more than 4 months treatment under this restriction

Compliance with Authority Required procedures – Streamlined Authority Code 4128

C4129

P4129

Severe pain

Continuing treatment

Patient must be undergoing palliative care;

Patient must be unable to take a solid dose form of a non‑steroidal anti‑inflammatory agent

Compliance with Authority Required procedures – Streamlined Authority Code 4129

(f)omit from the column headed “Purposes Code” for Circumstances Code C4159: P4159
(g)insert in numerical order after existing text:

C6149

Severe pain

Patient must be receiving palliative care.

C6150

Severe pain

Patient must be unable to take a solid dose form of a non-steroidal anti-inflammatory agent.

Patient must be undergoing palliative care.

C6196

Severe pain

Patient must be receiving palliative care.

Schedule 4, Part 1, entry for Nitrazepam
(a)omit:

P5610

CN5610

Insomnia

Continuing treatment

Patient must be receiving palliative care.

Compliance with Authority Required procedures

(b)omit:

P5662

CN5662

Insomnia

Initial treatment, for up to 4 months

Patient must be receiving palliative care.

Compliance with Authority Required procedures

(c)insert in numerical order after existing text:

P6175

CN6175

Insomnia

Patient must be receiving palliative care.

Compliance with Authority Required procedures

Schedule 4, Part 1, entry for Oxazepam
(a)omit:

P3655	CN3655	Initial supply, for up to 4 months, for a palliative care patient where anxiety is a problem	Compliance with Authority Required procedures
P3656	CN3656	Continuing supply for a palliative care patient where anxiety is a problem	Compliance with Authority Required procedures

(b)insert in numerical order after existing text:

P6176

CN6176

Anxiety

Patient must be receiving palliative care.

Compliance with Authority Required procedures

Schedule 4, Part 1, entry for Paracetamol
(a)omit:

C4940

P4940

Analgesia or fever

Initial treatment, for up to 4 months

Patient must be receiving palliative care; AND
Patient must be intolerant to alternative therapy

Compliance with Authority Required procedures - Streamlined Authority Code 4940

C4950

P4950

Analgesia or fever

Continuing treatment

Patient must be receiving palliative care; AND
Patient must be intolerant to alternative therapy

Compliance with Authority Required procedures - Streamlined Authority Code 4950

(b)insert in numerical order after existing text:

C6167

P6167

Analgesia or fever

Patient must be receiving palliative care; AND
Patient must be intolerant to alternative therapy.

Schedule 4, Part 1, entry for Phenoxybenzamine
substitute:

Phenoxybenzamine	C6145	Phaeochromocytoma
C6178	Neurogenic urinary retention

Schedule 4, Part 1, entry for Polyethylene Glycol 400 with Propylene Glycol
(a)omit:

C1359	Severe dry eye syndrome in patients who are sensitive to preservatives in multi‑dose eye drops	Compliance with Authority Required procedures – Streamlined Authority Code 1359
C2802	Severe dry eye syndrome in patients who are sensitive to preservatives in multi‑dose eye drops	Compliance with Authority Required procedures

(b)insert in numerical order after existing text:

C6172

Severe dry eye syndrome

Patient must be sensitive to preservatives in multi-dose eye drops.

Compliance with Authority Required procedures - Streamlined Authority Code 6172

Schedule 4, Part 1, entry for Protein hydrolysate formula with medium chain triglycerides
substitute:

Protein hydrolysate formula with medium chain triglycerides	C6137	Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein and soy protein Initial treatment for up to 6 months Patient must be up to the age of 24 months. Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist. The name of the specialist must be documented in the patient's medical records	Compliance with Authority Required procedures - Streamlined Authority Code 6137
C6138	Severe intestinal malabsorption including short bowel syndrome	Compliance with Authority Required procedures - Streamlined Authority Code 6138
C6148	Severe diarrhoea of greater than 2 weeks duration Patient must be aged less than 4 months.	Compliance with Authority Required procedures - Streamlined Authority Code 6148
C6157	Chronic liver failure with fat malabsorption	Compliance with Authority Required procedures - Streamlined Authority Code 6157
C6158	Enterokinase deficiency	Compliance with Authority Required procedures - Streamlined Authority Code 6158
C6166	Proven fat malabsorption	Compliance with Authority Required procedures - Streamlined Authority Code 6166
C6174	Cows' milk protein enteropathy and intolerance to soy protein Initial treatment The condition must not be isolated infant colic or reflux; AND Patient must have failed to respond to a strict soy-based cows' milk protein free diet. Patient must be up to the age of 24 months. Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepatologist, or in consultation with a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepatologist.	Compliance with Authority Required procedures - Streamlined Authority Code 6174
C6182	Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein and soy protein Continuing treatment Patient must be up to the age of 24 months. Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist. The name of the specialist must be documented in the patient's medical records	Compliance with Authority Required procedures - Streamlined Authority Code 6182
C6193	Cows' milk protein enteropathy and intolerance to soy protein Continuing treatment The condition must not be isolated infant colic or reflux; AND Patient must have demonstrated a clinical improvement with the protein hydrolysate formula with medium chain triglycerides. Patient must be up to the age of 24 months. Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepatologist, or in consultation with a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepatologist.	Compliance with Authority Required procedures - Streamlined Authority Code 6193
C6194	Biliary atresia	Compliance with Authority Required procedures - Streamlined Authority Code 6194
C6195	Cystic fibrosis	Compliance with Authority Required procedures - Streamlined Authority Code 6195
C6204	Cows' milk protein enteropathy and intolerance to soy protein The condition must not be isolated infant colic or reflux; AND Patient must have failed to respond to a strict soy-based cows' milk protein free diet. Patient must be older than 24 months of age. Must be treated by a specialist allergist, clinical immunologist, specialist paediatrician or specialist paediatric gastroenterologist and hepatologist. The name of the specialist must be documented in the patient's medical records	Compliance with Authority Required procedures - Streamlined Authority Code 6204
C6205	Chylous ascites	Compliance with Authority Required procedures - Streamlined Authority Code 6205
C6206	Chylothorax	Compliance with Authority Required procedures - Streamlined Authority Code 6206

Schedule 4, Part 1, entry for Rituximab
(a)omit:

C5980

Previously untreated CD20 positive diffuse large B-cell non-Hodgkin's lymphoma

Induction treatment

The treatment must be in combination with chemotherapy; AND
The condition must be previously untreated; AND
The condition must be symptomatic; AND
The treatment must be for induction treatment purposes only; AND
Patient must not receive more than 8 doses of rituximab in total, including intravenous and subcutaneous injections, and no more than 7 doses of subcutaneous rituximab under this restriction.
An initial dose of rituximab must be administered with rituximab intravenous injection. Subsequent doses may be administered with either intravenous or subcutaneous rituximab with no more than 8 doses in total.

Compliance with Authority Required procedures - Streamlined Authority Code 5980

C5992

Stage III or IV CD20 positive follicular B-cell non-Hodgkin's lymphoma

Maintenance therapy

Patient must have demonstrated a partial or complete response to the induction phase of treatment for previously untreated follicular B-cell Non-Hodgkin's lymphoma, received immediately prior to this current Authority application; AND
The treatment must be maintenance therapy; AND
Patient must not receive more than 12 doses or 2 years duration of treatment, whichever comes first, under this restriction.

Compliance with Authority Required procedures - Streamlined Authority Code 5992

(b)insert in the column headed “Purposes Code” for Circumstances Code C5998: P5998
(c)omit:

C6001

Stage III or IV CD20 positive follicular B-cell non-Hodgkin's lymphoma

Maintenance therapy

Patient must have demonstrated a partial or complete response to the induction phase of treatment for previously untreated follicular B-cell Non-Hodgkin's lymphoma, received immediately prior to this current Authority application; AND
The treatment must be maintenance therapy; AND
Patient must not receive more than 12 doses or 2 years duration of treatment, whichever comes first, under this restriction.

Compliance with Authority Required procedures - Streamlined Authority Code 6001

C6004

Stage III or IV CD20 positive follicular B-cell non-Hodgkin's lymphoma

Maintenance therapy

Patient must have demonstrated a partial or complete response to the induction phase of treatment for previously untreated follicular B-cell Non-Hodgkin's lymphoma, received immediately prior to this current Authority application; AND
The treatment must be maintenance therapy; AND
Patient must not receive more than 12 doses or 2 years duration of treatment, whichever comes first, under this restriction.

Compliance with Authority Required procedures - Streamlined Authority Code 6004

(d)insert in the column headed “Purposes Code” for Circumstances Code C6008:       P6008
(e)insert in the column headed “Purposes Code” for Circumstances Code C6011:       P6011
(f)insert in the column headed “Purposes Code” for Circumstances Code C6039:       P6039
(g)omit:

C6040

Previously untreated Stage III or IV CD20 positive follicular B-cell non-Hodgkin's lymphoma

Induction treatment

The treatment must be in combination with chemotherapy; AND
The condition must be previously untreated; AND
The condition must be symptomatic; AND
The treatment must be for induction treatment purposes only; AND
Patient must not receive more than 8 doses of rituximab in total, including intravenous and subcutaneous injections, and no more than 7 doses of subcutaneous rituximab under this restriction.
An initial dose of rituximab must be administered with rituximab intravenous injection. Subsequent doses may be administered with either intravenous or subcutaneous rituximab with no more than 8 doses in total.

Compliance with Authority Required procedures - Streamlined Authority Code 6040

C6058

Stage III or IV CD20 positive follicular B-cell non-Hodgkin's lymphoma

Maintenance therapy

Patient must have demonstrated a partial or complete response to the induction phase of treatment for previously untreated follicular B-cell Non-Hodgkin's lymphoma, received immediately prior to this current Authority application; AND
The treatment must be maintenance therapy; AND
Patient must not receive more than 12 doses or 2 years duration of treatment, whichever comes first, under this restriction.

Compliance with Authority Required procedures - Streamlined Authority Code 6058

(h)insert in numerical order after existing text:

C6161	P6161	Stage III or IV CD20 positive follicular B-cell non-Hodgkin's lymphoma Maintenance therapy Patient must have demonstrated a partial or complete response to induction treatment with either R-CHOP or R-CVP regimens for previously untreated follicular B-cell Non-Hodgkin's lymphoma, received immediately prior to this current Authority application; AND Patient must not have received bendamustine induction therapy; AND The treatment must be maintenance therapy; AND Patient must not receive more than 12 doses or 2 years duration of treatment, whichever comes first, under this restriction.	Compliance with Authority Required procedures - Streamlined Authority Code 6161
C6162	P6162	Previously untreated symptomatic indolent CD20 positive non-Hodgkin's lymphoma in combination with chemotherapy Induction treatment The treatment must be in combination with PBS-subsidised chemotherapy; AND The condition must be previously untreated; AND The condition must be symptomatic; AND The treatment must be for induction treatment purposes only; AND Patient must not receive more than the number of cycles of treatment recommended by standard guidelines for the partner chemotherapy under this restriction. An initial dose of rituximab must be administered with rituximab intravenous injection. Subsequent doses may be administered with either intravenous or subcutaneous rituximab with no more than 8 doses in total.	Compliance with Authority Required procedures - Streamlined Authority Code 6162
C6187	P6187	Previously untreated aggressive CD20 positive non-Hodgkin's lymphoma Induction treatment The treatment must be in combination with PBS-subsidised chemotherapy; AND The condition must be previously untreated; AND The treatment must be for induction treatment purposes only; AND Patient must not be eligible for stem cell transplantation if they have mantle cell lymphoma. An initial dose of rituximab must be administered with rituximab intravenous injection. Subsequent doses may be administered with either intravenous or subcutaneous rituximab with no more than 8 doses in total.	Compliance with Authority Required procedures - Streamlined Authority Code 6187

Schedule 4, Part 1, entry for Sorbitol with sodium citrate and sodium lauryl sulfoacetate
(a)omit:

C5641

P5641

Constipation

Continuing treatment

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 5641

(b)omit:

C5774

P5774

Constipation

Initial treatment, for up to 4 months

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 5774

(c)insert in numerical order after existing text:

C6139

P6139

Constipation

Patient must be receiving palliative care.

Schedule 4, Part 1, entry for Soy lethicin
substitute:

Soy lecithin

C6172

Severe dry eye syndrome

Patient must be sensitive to preservatives in multi-dose eye drops.

Compliance with Authority Required procedures - Streamlined Authority Code 6172

Schedule 4, Part 1, entry for Sterculia with frangula bark
(a)omit:

C5641

P5641

Constipation

Continuing treatment

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 5641

(b)omit:

C5774

P5774

Constipation

Initial treatment, for up to 4 months

Patient must be receiving palliative care.

Compliance with Authority Required procedures - Streamlined Authority Code 5774

(c)insert in numerical order after existing text:

C6139

P6139

Constipation

Patient must be receiving palliative care.

Schedule 4, Part 1, entry for Temazepam
(a)omit:

P5610

CN5610

Insomnia

Continuing treatment

Patient must be receiving palliative care.

Compliance with Authority Required procedures

(b)omit:

P5662

CN5662

Insomnia

Initial treatment, for up to 4 months

Patient must be receiving palliative care.

Compliance with Authority Required procedures

(c)insert in numerical order after existing text:

P6175

CN6175

Insomnia

Patient must be receiving palliative care.

Compliance with Authority Required procedures

Schedule 4, Part 1, entry for Triglycerides, medium chain
substitute:

Triglycerides, medium chain	C6134	Chylothorax	Compliance with Authority Required procedures - Streamlined Authority Code 6134
C6135	Cerebrospinal fluid glucose transporter defect Patient must require a ketogenic diet.	Compliance with Authority Required procedures - Streamlined Authority Code 6135
C6146	Long chain fatty acid oxidation disorders	Compliance with Authority Required procedures - Streamlined Authority Code 6146
C6147	Ketogenic diet Patient must have intractable seizures requiring treatment with a ketogenic diet; OR Patient must have a glucose transport protein defect; OR Patient must have pyruvate dehydrogenase deficiency.	Compliance with Authority Required procedures - Streamlined Authority Code 6147
C6155	Intractable childhood epilepsy Patient must require a ketogenic diet.	Compliance with Authority Required procedures - Streamlined Authority Code 6155
C6164	Fat malabsorption The condition must be due to liver disease; OR The condition must be due to short gut syndrome; OR The condition must be due to cystic fibrosis; OR The condition must be due to gastrointestinal disorders.	Compliance with Authority Required procedures - Streamlined Authority Code 6164
C6181	Chylous ascites	Compliance with Authority Required procedures - Streamlined Authority Code 6181
C6191	Dietary management of conditions requiring a source of medium chain triglycerides Patient must have chylous ascites; OR Patient must have chylothorax; OR Patient must have hyperlipoproteinaemia type 1; OR Patient must have long chain fatty acid oxidation disorders; OR Patient must have fat malabsorption due to liver disease; OR Patient must have fat malabsorption due to short gut syndrome; OR Patient must have fat malabsorption due to cystic fibrosis; OR Patient must have fat malabsorption due to gastrointestinal disorders.	Compliance with Authority Required procedures - Streamlined Authority Code 6191
C6203	Hyperlipoproteinaemia type 1	Compliance with Authority Required procedures - Streamlined Authority Code 6203

Schedule 4, Part 1, entry for Triglycerides — medium chain, formula
omit:

C5644	Chylothorax	Compliance with Authority Required procedures
C5645	Long chain fatty acid oxidation disorders	Compliance with Authority Required procedures
C5693	Fat malabsorption The condition must be due to liver disease; OR The condition must be due to short gut syndrome; OR The condition must be due to cystic fibrosis; OR The condition must be due to gastrointestinal disorders.	Compliance with Authority Required procedures
C5726	Chylous ascites	Compliance with Authority Required procedures
C5784	Hyperlipoproteinaemia type 1	Compliance with Authority Required procedures

substitute:

C6136	Long chain fatty acid oxidation disorders	Compliance with Authority Required procedures - Streamlined Authority Code 6136
C6156	Hyperlipoproteinaemia type 1	Compliance with Authority Required procedures - Streamlined Authority Code 6156
C6165	Chylous ascites	Compliance with Authority Required procedures - Streamlined Authority Code 6165
C6173	Fat malabsorption The condition must be due to liver disease; OR The condition must be due to short gut syndrome; OR The condition must be due to cystic fibrosis; OR The condition must be due to gastrointestinal disorders.	Compliance with Authority Required procedures - Streamlined Authority Code 6173
C6192	Chylothorax	Compliance with Authority Required procedures - Streamlined Authority Code 6192

Schedule 4, Part 1, entry for Trimethoprim
substitute:

Trimethoprim	P4243	CN4243	Prophylaxis of urinary tract infection	Compliance with Authority Required procedures – Streamlined Authority Code 4243
P6163	Prostatitis

Schedule 4, Part 1, after entry for Trimethoprim
insert:

Trimethoprim with sulfamethoxazole

P6201

CN6201

Prophylaxis of Pneumocystis jiroveci pneumonia

Compliance with Authority Required procedures - Streamlined Authority Code 6201

Schedule 4, Part 1, entry for Vitamins, minerals and trace elements with carbohydrate
substitute:

Vitamins, minerals and trace elements with carbohydrate

C6152

Dietary management of conditions requiring a highly restrictive therapeutic diet

Patient must have insufficient vitamin and mineral intake due to a specific diagnosis requiring a highly restrictive therapeutic diet; AND
Patient must be unable to adequately meet vitamin, mineral and trace element needs with other proprietary vitamin and mineral preparations.
Patient must be an infant or a child.

C6159

Dietary management of conditions requiring a highly restrictive therapeutic diet

Patient must have insufficient vitamin and mineral intake due to a specific diagnosis requiring a highly restrictive therapeutic diet; AND
Patient must be unable to adequately meet vitamin, mineral and trace element needs with other proprietary vitamin and mineral preparations.
Patient must be aged 3 years or older.

Schedule 4, Part 1, entry for Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose
substitute:

Whey protein formula supplemented with amino acids, long chain polyunsaturated fatty acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose

C6190

Chronic renal failure

Patient must require treatment with a low protein and a low phosphorus diet; OR
Patient must require treatment with a low protein, low phosphorus and low potassium diet.
Patient must be an infant or a young child.

Compliance with Authority Required procedures - Streamlined Authority Code 6190

Schedule 4, Part 1, entry for Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose
substitute:

Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose

C6190

Chronic renal failure

Patient must require treatment with a low protein and a low phosphorus diet; OR
Patient must require treatment with a low protein, low phosphorus and low potassium diet.
Patient must be an infant or a young child.

Compliance with Authority Required procedures - Streamlined Authority Code 6190

Schedule 5
insert as first entry:

Clopidogrel	GRP-15475	Tablet 75 mg (as besilate)	Oral	Clopidogrel-GA Clovix 75 Plidogrel
Clopidogrel	Tablet 75 mg (as hydrogen sulfate)	Oral	APO-Clopidogrel Blooms the Chemist Clopidogrel Chem mart Clopidogrel Clopidogrel AN Clopidogrel Winthrop Iscover Piax Plavix Terry White Chemists Clopidogrel
GRP-17110	Tablet 75 mg	Oral	Clopidogrel-DRLA
Tablet 75 mg (as besilate)	Oral	Clopidogrel GH Clopidogrel-GA Clovix 75 Plidogrel
Tablet 75 mg (as hydrogen sulfate)	Oral	APO-Clopidogrel Blooms the Chemist Clopidogrel Chem mart Clopidogrel Clopidogrel AN Clopidogrel RBX Clopidogrel Sandoz Clopidogrel Winthrop Iscover Piax Plavicor 75 Plavix Terry White Chemists Clopidogrel

Schedule 5, entry for Ondansetron in each of the forms: Tablet (orally disintegrating) 4 mg; and Tablet (orally disintegrating) 8 mg
insert in alphabetical order in the column headed “Brand”: Ondansetron ODT GH

Actions

Download as PDF Download as Word Document

Citations

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 5) (PB 41 of 2016) (Cth)

Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0